Eli Lilly to Acquire Dermira for $1.1B

 Eli Lilly to Acquire Dermira for $1.1B

Dermia‘s Lebrikizumab Receives the US FDA’s Fast Track Designation to Treat Atopic Dermatitis


  • Lilly acquires Dermira in all-cash transaction making total deal value ~$1.1B at $18.75/share representing premium of 86% to the 60-day volume-weighted average trading price of Dermira’s stock ending on January 9, 2020, with expected closure of agreement in Q1’20
  • The focus of the acquisition is to expand Eli Lilly’s immunology pipeline with the addition of Dermira’s P-III candidate, Lebrikizumab and its dermatology marketed portfolio with Qbrexza (glycopyrronium) cloth
  • Lebrikizumab is a mAb targeted to bind IL-13 with very high affinity, preventing the formation of IL-13Rα1/IL-4Rα heterodimer complex targeted for mod-to-sev atopic dermatitis in adolescent and adult. Qbrexza cloth is FDA approved medicated cloth to treat primary axillary hyperhidrosis (uncontrolled excessive underarm sweating)

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post